ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer VIEW MORE >>

Median overall survival was improved by 6.8 months with osimertinib as a first-line treatment for patients with metastatic, EGFR-mutant non–small cell lung cancer compared with erlotinib or gefitinib, despite crossover between arms, according to updated data from the phase III FLAURA study presented at the 2019 ESMO Congress.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.